Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Race Oncology Ltd. ( (AU:RAC) ) has shared an announcement.
Race Oncology Ltd has applied to the ASX for quotation of 27,762 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The modest new share issuance slightly expands the company’s listed capital base and reflects ongoing conversion of equity-linked instruments, with limited immediate impact on existing shareholders but incremental enhancement of the company’s tradable free float.
The most recent analyst rating on (AU:RAC) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Race Oncology Ltd. stock, see the AU:RAC Stock Forecast page.
More about Race Oncology Ltd.
Race Oncology Ltd (ASX: RAC) is an oncology-focused biotechnology company listed on the Australian Securities Exchange, developing cancer therapeutics and operating within the broader life sciences and healthcare sector.
Average Trading Volume: 268,075
Technical Sentiment Signal: Buy
Current Market Cap: A$517.2M
See more insights into RAC stock on TipRanks’ Stock Analysis page.